In a new study, published in Cell Reports, researchers from the William Harvey Research Institute at Queen Mary University of London used cells derived from urine to take the first step in generating an artificial adrenal gland.
The adrenal glands, located on the top of each kidney, are responsible for releasing different hormones. Adrenal gland disorders occur when the adrenal glands produce too much or too little of these hormones, which can affect growth, development, and metabolism.
In this Q&A, lead author Dr Leonardo Guasti explains the research and how it might be used to help develop future treatments for adrenal gland disorders.
What is new about the study?
“We have described for the first time the generation of steroid-producing cells (which we named human inducible steroidogenic cells, hiSCs) from skin, blood and urine of healthy donors and patients with congenital adrenal disorders. This process is generally called reprogramming.
“hiSCs were used to model adrenal diseases in a dish and provided a platform whereby to test intervention for new personalised treatments. Viability of hiSCs in vivo was also tested through implantation experiments in mice.”
How did you carry out the study?
“Reprogramming was achieved by forcing the expression of a single protein (a transcription factor) and the activation of two signalling pathways. Newly generated cells (hiSCs) expressed the enzymes responsible for steroid production and crucially were responsive to physiological stimuli, such as the secretion of corticol upon ACTH stimulation.
“The steroid profile of hiSCs generated from patients with a monogenic adrenal disorder (congenital adrenal hyperplasia) was altered, in keeping with their profile at diagnosis. When the non-mutated gene was re-introduced into these cells, the steroid profile was back to normal, and similar to that observed in hiSCs obtained from healthy donors.”
Why is the study important?
“It represents an entirely new concept for the study of the adrenal gland as the ability to generate donor-specific and functional adrenal-like cells will facilitate i) the next generation of cell-based treatments for adrenal insufficiency; ii) the modelling of adrenal specific diseases and iii) the testing of personalised interventions on cells derived from patients.”
What are the wider implications?
“It is a first step in generating an artificial adrenal gland which would benefit all patients with adrenal insufficiency. Regenerative medicine application for adrenal disorders have been neglected compared to other endocrine fields, such as the word-wide effort to generate functional endocrine pancreas to cure type-I diabetes. This study closes this gap.”